A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects With Light Chain (AL) Amyloidosis

Conditions

Multiple Myeloma

Phase III

Volunteers
Health Professionals

What is the purpose of this trial?

A Phase 3 study to evaluate the efficacy and safety of birtamimab plus standard of care compared to placebo plus standard of care in patients with AL amyloidosis in Mayo Stage IV.

Find out more about who can participate in this trial

Trial with
Prothena Biosciences Inc.
Start Date
04/26/2022
End Date
07/01/2024

For more information about this study, contact:

Kylie Boyhen

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Sabrina Browning, MD
Assistant Professor of Medicine (Hematology)

Sub-Investigators

Last Updated
04/28/2022
Study HIC
#2000030933

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects With Light Chain (AL) Amyloidosis

Conditions

Volunteers

Health Professionals

What is the purpose of this trial?

I'm interested in volunteering

Principal Investigator

Sub-Investigators

Contact Information